Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases

Ibrutinib, an irreversible Bruton's tyrosine kinase inhibitor, is an effective treatment for Waldenström's macroglobulinemia, chronic lymphocytic leukemia, and several other types of lymphoma. Studies prior to FDA approval in 2015 failed to demonstrate any hepatotoxicity. However, since th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tafesh, Zaid H., Coleman, Morton, Fulmer, Clifton, Nagler, Jerry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787434/
https://www.ncbi.nlm.nih.gov/pubmed/31607836
http://dx.doi.org/10.1159/000502605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787434/
https://www.ncbi.nlm.nih.gov/pubmed/31607836
http://dx.doi.org/10.1159/000502605

Ejemplares similares